Therapeutic Targets
With our lead drug candidate, CRX-100, we have used an intellectual property portfolio, developed by the company’s founders and exclusively licensed from Stanford University, to create a first-in-class immunotherapy that pairs the power of an oncolytic virus with the tumor-locating ability of cytokine-induced killer (CIK) cells.
16744
page-template,page-template-full_width,page-template-full_width-php,page,page-id-16744,bridge-core-1.0.6,ajax_fade,page_not_loaded,,qode_grid_1200,qode-theme-ver-18.2,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.0.5,vc_responsive
 

Therapeutic Targets

Acute Myeloid Leukemia

 

Acute myeloid leukemia (AML) is a blood disorder characterized by uncontrolled proliferation of a type of immature white blood cells called “myeloid cells”, which causes failure of the bone marrow to function properly. AML is the most common type of leukemia in adults.

 

COVID-19 Associated Acute Lung Injury

 

Acute lung injury is a rapidly progressive form of respiratory failure that occurs in some people, especially the elderly or those with pre-existing illness, who are infected with COVID-19. It is the major cause of morbidity and mortality that is associated with COVID-19 infection.

 

Metastatic Pancreatic Cancer

 

Pancreatic cancer is projected to become the second leading cause of cancer-related deaths in the US by 2030. Its prognosis remains extremely poor, with a 5-year survival rate of just 8%. Over half of patients have metastatic disease at the time of diagnosis, and most patients who receive potentially curative surgery ultimately relapse with metastatic disease. The treatment available for patients with metastatic pancreatic cancer patients consists of systemic chemotherapy which seeks to prolong survival, relieve symptoms such as abdominal pain and gastrointestinal discomfort, and maintain or improve quality of life.

 

Recurrent/refractory multiple myeloma

 

Although great strides have been made in the treatment of myeloma, relapse is common, and the disease tends to become more refractory with each successive line of treatment. New treatments, especially those with lesser side effects, are greatly needed.

 

Recurrent pediatric sarcoma

 

Although pediatric sarcoma is amenable to initial treatment with surgery and chemotherapy, many children develop relapsed disease, for which new, more effective treatment is greatly needed.

microscope and Doctor holding tablet